A randomized phase III trial of palonosetron plus dexamethasone (day 1) versus palonosetron plus dexamethasone (day 1-3) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy, not including a combination of anthracycline plus cyclophosphamide

被引：0
|
作者：
Sasaki, K. [1 ]
Okita, K. [2 ]
Yuki, S. [3 ]
Takahashi, Y. [4 ]
Abe, M. [5 ]
Hatanaka, K. [6 ]
Isobe, H. [7 ]
Sogabe, S. [8 ]
Oba, K. [9 ]
Komatsu, Y. [10 ]
机构：
[1] Otaru Ekisaikai Hosp, Otaru, Hokkaido, Japan
[2] Sapporo Med Univ Hosp, Sapporo, Hokkaido, Japan
[3] Hokkaido Univ Hosp, Sapporo, Hokkaido 060, Japan
[4] Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[5] Sapporo Kosei Gen Hosp, Sapporo, Hokkaido, Japan
[6] Hakodate Municipal Hosp, Hakodate, Hokkaido, Japan
[7] KKR Sapporo Med Ctr, Sapporo, Hokkaido, Japan
[8] Kushiro Rosai Hosp, Kushiro, Hokkaido, Japan
[9] Hokkaido Univ Hosp, Translat Res & Clin Trial Ctr, Sapporo, Hokkaido 060, Japan
[10] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido 060, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1303
引用
收藏
页码：S267 / S268
页数：2
相关论文
共 50 条
  • [21] Palonosetron (PALO) plus aprepitant (APREP) and dexamethasone (DEX) for the prevention of chemotherapy-induced nausea and vomiting (CINV) after emetogenic chemotherapy (CT)
    Grote, T
    Hajdenberg, J
    Cartmell, A
    Ferguson, S
    Ginkel, A
    Gallagher, S
    Charu, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 794S - 794S
  • [22] Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer
    Einhorn, Lawrence H.
    Brames, Mary J.
    Dreicer, Robert
    Nichols, Craig R.
    Cullen, Michael T., Jr.
    Bubalo, Joseph
    SUPPORTIVE CARE IN CANCER, 2007, 15 (11) : 1293 - 1300
  • [23] Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer
    Lawrence H. Einhorn
    Mary J. Brames
    Robert Dreicer
    Craig R. Nichols
    Michael T. Cullen
    Joseph Bubalo
    Supportive Care in Cancer, 2007, 15 : 1293 - 1300
  • [24] Phase II study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapy
    Ioroi, Takeshi
    Furukawa, Junya
    Kume, Manabu
    Hirata, Sachi
    Utsubo, Yuko
    Mizuta, Naomi
    Miyake, Hideaki
    Fujisawa, Masato
    Hirai, Midori
    SUPPORTIVE CARE IN CANCER, 2018, 26 (05) : 1419 - 1423
  • [25] Phase II study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapy
    Takeshi Ioroi
    Junya Furukawa
    Manabu Kume
    Sachi Hirata
    Yuko Utsubo
    Naomi Mizuta
    Hideaki Miyake
    Masato Fujisawa
    Midori Hirai
    Supportive Care in Cancer, 2018, 26 : 1419 - 1423
  • [26] Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
    Ralph Boccia
    Steven Grunberg
    Edwin Franco-Gonzales
    Edward Rubenstein
    Daniel Voisin
    Supportive Care in Cancer, 2013, 21 : 1453 - 1460
  • [27] Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
    Boccia, Ralph
    Grunberg, Steven
    Franco-Gonzales, Edwin
    Rubenstein, Edward
    Voisin, Daniel
    SUPPORTIVE CARE IN CANCER, 2013, 21 (05) : 1453 - 1460
  • [28] Ramosetron versus palonosetron in combination with aprepitant and dexamethasone for the control of highly emetogenic chemotherapy-induced nausea and vomiting
    Kwon, J. H.
    Kang, J-H.
    Lee, Y-G.
    Park, K. U.
    An, H. J.
    Sohn, J.
    Seol, Y. M.
    Lee, H.
    Yun, H-J.
    Ahn, J. S.
    Kim, H. J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] Palonosetron (PALO), administered orally or intravenously (IV), plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV)
    Boccia, R. V.
    Gonzalez, E. F.
    Pluzanska, A. G.
    Clerici, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study
    Kitayama, Hiromitsu
    Tsuji, Yasushi
    Sugiyama, Junko
    Doi, Ayako
    Kondo, Tomohiro
    Hirayama, Michiaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (06) : 1051 - 1056
12345